CBCN study plan

Classify the major systemic therapy families (cytotoxic chemotherapy, endocrine therapy, HER2-directed agents, CDK4/6 inhibitors, immunotherapy, antibody-drug conjugates, PARP inhibitors) by mechanism and the patient profile each is used for

Construct a drug-by-toxicity matrix for at least 15 high-yield agents, tagging each toxicity as acute, cumulative, delayed, or infusion-related

Sequence the surgical phases of breast cancer care (breast-conserving surgery, mastectomy, sentinel node biopsy, axillary dissection, reconstruction) and list two preoperative and two postoperative nursing priorities for each

Explain radiation delivery approaches and the associated skin, fatigue, and pulmonary management bundles

Translate two common regimens into a nursing care calendar that marks premedication, expected nadir window, lab checkpoints, and assessment questions for each visit

Differentiate febrile neutropenia from other causes of fever in the treated patient and state the immediate response bundle and escalation triggers

Contrast extravasation management for vesicant versus irritant versus non-vesicant agents, including the first three actions for each

Match antiemetic prophylaxis to emetogenic risk tier and identify when to add a neurokinin-1 antagonist, olanzapine, or breakthrough dosing

Grade eight common treatment toxicities (mucositis, diarrhea, hand-foot syndrome, peripheral neuropathy, fatigue, skin reaction, nausea, constipation) and pair each grade with a specific nursing action

Design a stepped cancer pain plan covering opioid initiation, bowel prophylaxis, breakthrough dosing principles, and opioid-safety teaching points

Outline lymphedema risk-reduction teaching and identify the clinical findings and timing that warrant referral to a certified lymphedema therapist

Select combined pharmacologic and nonpharmacologic interventions for chemotherapy-induced peripheral neuropathy, cancer-related fatigue, and insomnia, citing the rationale for each

Compare screening modalities by age and risk category, stating the recommended interval, the modality's key limitation, and the population for which it is not appropriate

Interpret BI-RADS assessment categories and state the follow-up or biopsy implication of each

Sequence the diagnostic pathway from an abnormal finding through imaging, tissue sampling, and pathology reporting, including what the nurse confirms at each handoff

Explain TNM staging and stage grouping, and connect stage, grade, and biomarker status (ER, PR, HER2, Ki-67) to prognosis and treatment direction

Compare validated risk-assessment tools (Gail-style models, Tyrer-Cuzick, BRCA-focused models), stating what each estimates and where each under- or over-estimates risk

Differentiate average, moderate, and high lifetime risk categories and specify the surveillance each category implies

Apply hereditary referral criteria and explain the patient and family implications of a pathogenic variant in BRCA1, BRCA2, PALB2, or TP53

Summarize risk-reducing options, including chemoprevention agents, risk-reducing surgery, and modifiable lifestyle factors, with the strength of evidence behind each

Select validated screening tools for distress, anxiety, depression, and financial toxicity, and state the score or finding that triggers referral

Build a survivorship plan covering surveillance schedule, late cardiac and bone effects, fertility and sexual health, and recurrence-awareness teaching

Apply teach-back and plain-language techniques when reviewing a treatment or survivorship plan, and document a shared decision-making exchange

Map care-coordination handoffs among surgery, medical oncology, radiation oncology, rehabilitation, and primary care, naming the information that must travel with the patient

Re-audit the running weak-topic log from weeks 1 through 6 and close at least five identified gaps with targeted study and self-testing

Explain cultural, spiritual, caregiver, and sexual- and gender-minority considerations that shape breast cancer communication and decision-making

Complete timed case-based item sets across all five domains and categorize each error as knowledge, misread, or reasoning failure

Rehearse handling of ethical and care-coordination scenarios such as fertility preservation urgency, clinical trial enrollment, and transition to palliative care

Complete two timed 100-question mixed practice sets and analyze item-level errors by domain and by error type

Review a condensed high-yield fact sheet for each domain, prioritizing items missed twice or more

Rehearse test-day pacing, flagging, and break strategy using the same timing as the actual exam

Consolidate the highest-risk recall facts into a single last-look sheet organized by domain